When I started researching what actually matters for a healthy pregnancy, I kept running into the same class of chemicals in the most unexpected places: the pan I scrambled eggs in, the basket in my air fryer, the water coming out of my tap. PFAS -- per- and polyfluoroalkyl substances -- are everywhere in modern kitchens and homes, and they don't just sit inert. They enter the body, accumulate over years, and they have a particular affinity for the biological systems that drive fertility and fetal development.
This isn't alarmism. The research on PFAS and reproductive health is some of the most robust in the field of environmental medicine, backed by decades of epidemiology spanning hundreds of thousands of study participants across multiple countries. Understanding what the science actually says -- and what you can practically do about it -- is what this guide is for.
How PFAS Disrupt Reproductive Biology
PFAS are endocrine disruptors, meaning they interfere with the hormonal signaling systems the body uses to regulate virtually every aspect of reproduction: the menstrual cycle, sperm production, ovulation, fertilization, implantation, placental development, and fetal growth.
The primary mechanism is structural mimicry. Several PFAS compounds -- particularly PFOA -- resemble thyroid hormones and compete with them for binding to transport proteins, suppressing the free hormone that drives everything from ovulation timing to fetal brain development. PFAS also bind to peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptors that regulate fatty acid metabolism, insulin sensitivity, and inflammatory pathways -- all of which are critical in early pregnancy and placental function.
Beyond mimicry, PFAS cause oxidative stress in reproductive tissues, disrupting the mitochondrial function that sperm depend on for motility and that eggs depend on for developmental competence after fertilization.
PFAS and Male Fertility
The evidence connecting PFAS to reduced male fertility is strong and spans biological mechanisms, animal studies, and large-scale human epidemiology.
In human studies, higher serum PFAS levels are consistently associated with poorer semen parameters across all three key metrics:
Sperm count: Multiple cohort studies find inverse associations between PFAS serum levels and total sperm count. Men in the highest PFOS exposure quartiles consistently show lower sperm concentrations than those in the lowest quartiles.
Sperm motility: A 2023 review in Frontiers in Endocrinology synthesizing epidemiological and experimental evidence found that seminal PFOA, PFOS, and perfluorohexanesulfonate (PFHxS) were significantly associated with decreased progressive and total sperm motility. At the cellular level, PFOS has been shown to disrupt mitochondrial membrane potential and reduce calcium signaling in sperm -- both of which are mechanistically required for forward movement.
Sperm morphology: Arctic and European population studies found that men in the highest PFOS exposure group had approximately 35% lower proportions of normally shaped sperm compared to those in the lowest group. PFOA, PFOS, and related compounds are also associated with higher rates of sperm with coiled tails and structural head abnormalities.
The C8 Health Project -- the landmark study of approximately 69,000 people exposed to PFOA-contaminated drinking water near DuPont's Washington Works facility in West Virginia -- provided some of the earliest and largest-scale human evidence linking PFAS to adverse health outcomes, including reproductive effects. The C8 Science Panel's assessments of that population, conducted between 2005 and 2013, documented associations between PFOA exposure and multiple health endpoints that have since been replicated in independent cohorts worldwide.
The biological mechanism is not speculative: PFOS has been confirmed to increase reactive oxygen species (ROS) in sperm mitochondria and reduce viability in a dose-dependent fashion, independent of lifestyle confounders like smoking or body weight.
PFAS and Female Fertility
For women, PFAS act at multiple points in the reproductive axis -- the hypothalamic-pituitary-ovarian signaling cascade that orchestrates the menstrual cycle, ovulation, and the hormonal environment needed for conception and early pregnancy maintenance.
Time-to-pregnancy: The Danish National Birth Cohort (DNBC), which enrolled over 90,000 pregnant women beginning in the late 1990s, provided foundational data here. Analyses of DNBC participants found that women with higher serum PFOS and PFOA concentrations were significantly more likely to report time-to-pregnancy greater than 12 months -- the clinical definition of subfertility -- or to have used infertility treatment. The 40% fertility reduction finding cited in recent coverage traces back to this family of large cohort studies.
Irregular cycles: In a subset of 1,240 pregnant women randomly selected from the Danish National Birth Cohort, women with higher PFOA and PFOS exposure were more likely to report irregular menstrual periods retroactively. Women in the highest PFOS tertile showed the most pronounced association with cycle irregularity, consistent with PFAS disruption of LH and FSH pulsatility.
Endometriosis: Several studies have documented associations between serum PFOA and PFNA (perfluorononanoate) and increased odds of endometriosis diagnosis. The mechanism is plausible: PFAS-driven estrogenic activity and inflammatory signaling could promote ectopic endometrial tissue growth. While causality has not been established in RCTs (which are ethically impossible for chemical exposure studies), the epidemiological signal is consistent across independent datasets.
Ovarian reserve: PFAS exposure has been associated with reduced anti-Mullerian hormone (AMH) levels in women of reproductive age -- a key marker of ovarian reserve and egg quantity. Lower AMH is associated with poorer response to fertility treatment and earlier menopause.
The Norwegian Mother-Father-Child Cohort (MoBa), one of the largest birth cohort studies in the world with over 100,000 pregnancies enrolled, has contributed substantially to understanding how environmental exposures including PFAS affect fecundability -- the per-cycle probability of conception. MoBa data have documented PFAS bioaccumulation in women in the years following pregnancy and lactation, and multiple analyses from this cohort have influenced regulatory policy in the EU.
PFAS Cross the Placenta: What Cord Blood Studies Show
One of the most consequential findings in PFAS reproductive research is that these chemicals do not stop at the maternal body. They cross the placenta.
Cord blood studies consistently detect PFAS in newborns at concentrations that track closely with maternal serum levels. Transplacental transfer efficiency varies by compound -- longer-chain PFAS tend to transfer more efficiently than shorter-chain variants -- but no PFAS class has been found to be categorically excluded from fetal circulation. Studies find cord blood PFAS concentrations at roughly 20-50% of matched maternal serum levels for the most common compounds.
This matters because the timing of PFAS exposure determines the biological stakes. Fetal exposure during the first trimester -- when organ systems including the gonads, brain, and thyroid are being laid down -- occurs against a developmental backdrop where cells are exquisitely sensitive to hormonal disruption. The fetal thyroid, for instance, does not begin producing its own hormones until around week 12 of gestation; before that point, the fetus depends entirely on maternal thyroid hormones, which PFAS are known to suppress. Even modest maternal free T4 reductions during this window carry measurable consequences for child neurodevelopment and IQ.
In addition to thyroid effects, prenatal PFAS exposure is associated with altered development of the fetal gonads -- the earliest programming of the reproductive axis that will determine reproductive capacity decades later.
Pregnancy Outcomes: Preeclampsia, Gestational Diabetes, and Birth Weight
Beyond fertility, PFAS exposure during pregnancy is associated with a cluster of serious obstetric outcomes that affect both maternal and fetal health.
Preeclampsia: A systematic review and meta-analysis of PFAS and adverse pregnancy outcomes found positive associations between PFOS exposure and preeclampsia risk (pooled OR per 1-log increase in serum PFOS: 1.27, 95% CI: 1.06-1.51). A Swedish study of a highly exposed community near Ronneby -- where AFFF-contaminated drinking water produced PFAS serum levels well above population averages -- found elevated rates of both gestational hypertension and preeclampsia compared to unexposed controls. The biological mechanism likely involves PFAS disruption of PPAR pathways that regulate placental vascular development and the angiogenic balance critical for normal blood pressure regulation in pregnancy.
Gestational diabetes: Meta-analysis published through 2025 found that each doubling of serum PFOA was associated with approximately 23% higher odds of gestational diabetes (OR 1.23) in nested case-control study designs. For PFOS, each doubling of serum concentration was associated with approximately 13% higher odds in prospective studies. The plausible mechanism -- PFAS interference with insulin receptor signaling and glucose metabolism via PPAR-gamma activation -- is supported by in vitro evidence.
Low birth weight and fetal growth: The evidence on birth weight is more mixed across studies, but the overall direction is consistent: higher PFAS exposure is associated with reduced fetal growth metrics in multiple large cohorts. The biological logic connects to PFAS-mediated thyroid disruption -- thyroid hormones are direct regulators of fetal growth, and even subclinical maternal hypothyroxinemia during gestation is associated with lower birth weight.
Breastfeeding and PFAS: What the Evidence and Guidelines Say
Breastmilk is a known transfer route for PFAS. Studies confirm that PFOS, PFOA, and related compounds are detectable in human breast milk, and that longer duration of breastfeeding is associated with progressively higher infant serum PFAS levels.
This finding has caused genuine anxiety among new mothers, and it deserves a clear, evidence-grounded answer: the WHO, the American Academy of Pediatrics, and the American College of Obstetricians and Gynecologists all continue to recommend breastfeeding for the vast majority of mothers, including those with PFAS exposure. The immunological, nutritional, microbiome, and bonding benefits of breastfeeding are substantial, well-documented, and persistent into childhood and adulthood. The scientific and public health consensus is that for most mothers, these benefits outweigh the risks of PFAS transfer through breast milk.
Importantly, breastfeeding also facilitates maternal PFAS elimination. Studies of serum half-lives have found that women in their fertile years eliminate PFAS faster than men -- partly because menstruation, pregnancy, and lactation all contribute to transferring maternal PFAS burden out of the body. The mean serum half-life of PFOA in women of reproductive age is roughly 2 years, compared to approximately 2.8 years in men.
The most impactful action for mothers concerned about PFAS and breastfeeding is not to stop breastfeeding -- it is to reduce ongoing PFAS intake during the breastfeeding period so that the concentration gradient driving milk contamination is as low as possible. That means water filters, PFAS-free cookware, and avoiding PFAS-treated food packaging.
Preconception PFAS Reduction: What Actually Helps
Because PFAS accumulate over years and have serum half-lives measured in years rather than days, the preconception period -- ideally beginning 6-12 months before attempting to conceive -- is the most important intervention window.
Water filtration is the highest-impact single action. Drinking water is consistently identified as the primary ongoing PFAS exposure route for most people. An estimated 176 million Americans have detectable PFAS in tap water. Standard pitcher filters like Brita and PUR do not reliably remove PFAS. The only technologies with strong evidence are reverse osmosis (NSF/ANSI 58 certified, removes 95-99% of PFAS including short-chain variants) and activated carbon block filters (NSF/ANSI 53 or P473 certified, removes 70-99% of long-chain PFAS). For households with pregnant women or those actively trying to conceive, under-sink reverse osmosis is the standard-of-care recommendation.
Replace nonstick cookware and air fryer baskets. PTFE-coated pans and air fryer baskets are direct PFAS exposure sources -- especially when scratched or preheated empty. Ceramic-coated alternatives (GreenPan Thermolon, Caraway), stainless steel, or cast iron eliminate this exposure pathway entirely. For cookware, the swap is permanent: you buy it once and it's done.
Reduce PFAS-treated food packaging. Fast food wrappers, microwave popcorn bags, and some parchment paper brands use PFAS coatings. Cooking at home with PFAS-free cookware and choosing glass or stainless steel food storage removes a significant exposure route.
Minimize carpet and upholstery with stain-resistant treatments. Scotchgard-type treatments are PFAS-based. During preconception and pregnancy, avoid re-treating carpets or purchasing new stain-resistant furniture -- PFAS in household dust is a measurable exposure pathway, particularly for toddlers who crawl and put hands to mouth.
Understand what you cannot eliminate quickly. PFAS body burden accumulated over years does not reverse in weeks. PFOA has a serum half-life of roughly 2-3 years; PFOS and PFHxS are longer. What you can do in the preconception window is stop adding to that burden while the body gradually clears what's already there. Every month of reduced exposure before conception lowers the maternal serum level that will determine placental and cord blood transfer during pregnancy.
There is emerging research on interventions that may accelerate PFAS elimination -- including cholestyramine (a bile acid sequestrant that interrupts enterohepatic PFAS recycling) and dietary oat fiber (beta-glucan, which may bind PFAS in the gut). These remain investigational and require guidance from a healthcare provider before use in preconception or pregnancy contexts.
The Cumulative Burden: PFAS Does Not Act Alone
PFAS exposure during preconception and pregnancy rarely occurs in isolation. Most people are simultaneously exposed to BPA, phthalates, and other endocrine-disrupting chemicals -- a "cocktail effect" that is harder to study but likely compounds the reproductive disruption from any single chemical. This is why the preconception approach that research consistently supports is not targeted elimination of one chemical, but a systematic reduction in total synthetic chemical load: PFAS-free cookware, endocrine-disruptor-aware personal care products, filtered water, and reduced reliance on processed food in plastic packaging.
The science is genuinely daunting -- these chemicals are everywhere, they've been building in the global environment for 70 years, and they sit in our bodies right now. But the trajectory is controllable. Serum PFAS levels in the US population have already fallen significantly since the phase-out of PFOA and PFOS production, demonstrating that reduced exposure translates to reduced body burden at a population scale. At the individual level, the same principle holds: reduce the inputs, and the body gradually does the rest.